Opinion|Videos|February 3, 2025
Setting Goals for Pediatric Atopic Dermatitis Treatment
Panelists discuss the goals of treating atopic dermatitis, focusing on symptom control and quality of life, with treatment differing for children and adults, and emphasize using assessment tools such as Eczema Area and Severity Index (EASI)-75/90, Investigator Global Assessment (IGA), and itch scores alongside patient-reported outcomes to guide decisions while also considering disease severity and the impact of atopic comorbidities in treatment approaches.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the goals of treatment for a patient with atopic dermatitis?
- How do treatment goals differ for atopic dermatitis in the pediatric population compared with adults?
- How do you leverage standard assessment tools such as EASI-75/90, IGA, and itch scores vs patient- and caregiver-reported outcomes?
- When considering disease severity and a treatment approach, how do you determine systemic eligibility in a pediatric patient?
- Does the presentation of atopic comorbidities dictate a treatment approach?
Advertisement
Related to this article
FDA approved levacetylleucine (Aqneursa) for ataxia in ataxia-telangiectasia, the first therapy for the disease, in patients 15 kg or heavier.
Tallie Z. Baram, MD, talks about how adding a measure of childhood unpredictability to ACEs screening may help pediatricians identify children at risk for mental health problems.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
The FDA granted priority review to efzimfotase alfa for HPP in patients aged 2 years and older; a decision is expected in the first half of 2027.
Adolescent VALIANT subgroup data show pegcetacoplan cut proteinuria 75% vs placebo, supporting its expanded pediatric kidney indication.
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), a one-time AAV9 gene therapy, as the first treatment for pediatric MPS IIIA (Sanfilippo syndrome type A).
Aquestive resubmitted its NDA for dibutepinephrine sublingual film Anaphylm, citing new human factors and PK data addressing the FDA's CRL.
Melissa Wallach, MD, FAAP, discusses what pediatricians should know about updated screening, supplementation, and treatment recommendations for iron deficiency.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Updated AAP guidance changes iron deficiency screening and treatment in children
2
FDA approves levacetylleucine as first treatment for ataxia in ataxia-telangiectasia
3
FDA grants priority review to efzimfotase alfa for hypophosphatasia in patients aged 2 years and older
4
Pegcetacoplan reduces proteinuria, stabilizes kidney function in adolescents with C3G and IC-MPGN
5